Vadadustat

Catalog No.S6490 Synonyms: AKB-6548, B-506, PG-1016548

For research use only.

Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.

Vadadustat Chemical Structure

CAS No. 1000025-07-9

Selleck's Vadadustat has been cited by 1 Publication

Purity & Quality Control

Choose Selective HIF Inhibitors

Other HIF Products

Biological Activity

Description Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.
Targets
PH2 [1] FIH(factor inhibiting HIF) [1]
0.029 μM 29 μM
In vitro

Vadadustat works by active site iron chelating mechanisms in terms of inhibiting isolated PHD2[1].

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 306.70
Formula

C14H11ClN2O4

CAS No. 1000025-07-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05082584 Suspended Drug: Vadadustat Anemia of Chronic Kidney Disease Akebia Therapeutics May 2022 Phase 3
NCT05082571 Suspended Drug: vadadustat Anemia of Chronic Kidney Disease Akebia Therapeutics May 2022 Phase 3
NCT03992066 Completed Drug: Vadadustat|Drug: Darbepoetin alfa|Drug: Epoetin alfa Anemia Associated With Chronic Kidney Disease Akebia Therapeutics May 28 2019 Phase 1
NCT03799627 Completed Drug: Vadadustat|Drug: Epoetin Alfa|Drug: Vadadustat TIW Anemia|Dialysis-dependent Chronic Kidney Disease Akebia Therapeutics January 31 2019 Phase 2
NCT03789032 Completed Drug: Vadadustat|Drug: Rabeprazole Drug Interaction Potentiation|Pharmacokinetics Akebia Therapeutics October 3 2018 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Vadadustat | Vadadustat supplier | purchase Vadadustat | Vadadustat cost | Vadadustat manufacturer | order Vadadustat | Vadadustat distributor